- Marketwired•15 days agoCannabis Science Inc. (CBIS) and Dana Farber/Harvard Cancer Center (DF/HCC) Announce Joint Research and Drug Development Agreement; Collaborative Research Agreement
Cannabis Science, Inc. , a U.S. company specializing in the development of cannabinoid-based medications, is proud to announce a collaborative research agreement with Dana Farber/Harvard Cancer Center ...
- Marketwired•last monthCannabis Science Orders Multiple Greenhouse Structures for its 2nd Pilot 33,000 Sq. Ft. Drug Development Facility Buildout in Douglas County, Nevada
Cannabis Science, Inc. , a U.S. company specializing in the development of cannabinoid-based medications, has started work on its second 33,000 sq. ft. pilot cannabinoid drug development and manufacturing ...
- Capital Cube•2 months ago
Categories: Yahoo Finance Get free summary analysis Cannabis Science, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Cannabis Science, Inc. – Ignyta, Inc., Elite Pharmaceuticals, Inc., Radius Health Inc and Chimerix, Inc. (RXDX-US, ELTP-US, RDUS-US and CMRX-US) that have also reported for this period. Highlights ... Read more (Read more...)
CBIS : Summary for CANNABIS SCIENCE I COM USD0.001 - Yahoo Finance
Cannabis Science, Inc. (CBIS)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.11 - 0.14|
|52 Week Range||0.01 - 0.14|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-13.47|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|